Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)

References

• Centers for Disease Control and Prevention. Biggest threats and data; 2020. Atlanta, GA. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed May 22, 2020.
   Google Scholar
• Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173(9):1037–1042. doi:10.1503/cmaj.050978
   PubMed Web of Science ®Google Scholar
• Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med (Lond). 2018;18(3):237–241. doi:10.7861/clinmedicine.18-3-237
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–994. doi:10.1093/cid/ciy149
   PubMed Web of Science ®Google Scholar
• Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345–354. doi:10.1093/cid/ciu313
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431. doi:10.1056/NEJMoa0910812
   PubMed Web of Science ®Google Scholar
• Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016;62(5):574–580. doi:10.1093/cid/civ958
   PubMed Web of Science ®Google Scholar
• Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(Suppl 2):S154–161. doi:10.1093/cid/cis462
   PubMed Web of Science ®Google Scholar
• Gerding DN, Kelly CP, Rahav G, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis. 2018;67(5):649–656. doi:10.1093/cid/ciy171
   PubMed Web of Science ®Google Scholar
• Olsen MA, Yan Y, Reske KA, Zilberberg M, Dubberke ER. Impact of Clostridium difficile recurrence on hospital readmissions. Am J Infect Control. 2015;43(4):318–322. doi:10.1016/j.ajic.2014.12.020
   PubMed Web of Science ®Google Scholar
• Tran MN, Kullar R, Goldstein EJC. Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection. Expert Opin Investig Drugs. 2019;28(4):323–335. doi:10.1080/13543784.2019.1581763
   PubMed Web of Science ®Google Scholar
• Xu WC, Silverman MH, Yu XY, Wright G, Brown N. Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. Bioorg Med Chem. 2019;27(15):3209–3217. doi:10.1016/j.bmc.2019.06.017
   PubMed Web of Science ®Google Scholar
• Hammond RA, Barnes MH, Mack SL, Mitchener JA, Brown NC. Bacillus subtilis DNA polymerase III: complete sequence, overexpression, and characterization of the polC gene. Gene. 1991;98(1):29–36. doi:10.1016/0378-1119(91)90100-P
   PubMed Web of Science ®Google Scholar
• Pacitti DF, Barnes MH, Li DH, Brown NC. Characterization and overexpression of the gene encoding Staphylococcus aureus DNA polymerase III. Gene. 1995;165(1):51–56. doi:10.1016/0378-1119(95)00377-I
   PubMed Web of Science ®Google Scholar
• Foster KA, Barnes MH, Stephenson RO, et al. DNA polymerase III of Enterococcus faecalis: expression and characterization of recombinant enzymes encoded by the polC and dnaE genes. Protein Expr Purif. 2003;27(1):90–97. doi:10.1016/S1046-5928(02)00577-6
   PubMed Web of Science ®Google Scholar
• Torti A, Lossani A, Savi L, et al. Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds. Curr Enzym Inhib. 2011;7(3):147–153. doi:10.2174/157340811798807597
   PubMedGoogle Scholar
• Xu WC, Wright GE, Brown NC, et al. 7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity. Bioorg Med Chem Lett. 2011;21(14):4197–4202. doi:10.1016/j.bmcl.2011.05.093
   PubMed Web of Science ®Google Scholar
• Dvoskin S, Xu WC, Brown NC, Yanachkov IB, Yanachkova M, Wright GE. A novel agent effective against Clostridium difficile infection. Antimicrob Agents Chemother. 2012;56(3):1624–1626. doi:10.1128/AAC.06097-11
   PubMed Web of Science ®Google Scholar
• van Eijk E, Boekhoud IM, Kuijper EJ, Bos-Sanders IMJG, Wright G, Smits WK. Genome location dictates the transcriptional response to sub-inhibitory concentrations of PolC-inhibitors in Clostridium difficile. bioRxiv. 2018.
   Google Scholar
• van Eijk E, Boekhoud IM, Kuijper EJ, Bos-Sanders I, Wright G, Smits WK. Genome location dictates the transcriptional response to PolC inhibition in Clostridium difficile. Antimicrob Agents Chemother. 2019;63:2. doi:10.1128/AAC.00779-19
   Web of Science ®Google Scholar
• Garey K. A Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Phase 1 Study to Determine the Safety, Pharmacokinetics, Food, and Fecal Microbiome Effects of ACX 362E Administered Orally to Healthy Subjects. Washington DC: IDWeek; 2019.
   Google Scholar
• Acurx Pharmaceuticals. ACX-375C. Available from: https://www.acurxpharma.com/pipeline/acx-375c. Accessed June 1, 2020.
   Google Scholar
• Wikipedia. Glutamine. Available from: https://en.wikipedia.org/w/index.php?title=glutamine&oldid=956552063. Accessed June 3, 2020.
   Google Scholar
• Carneiro BA, Fujii J, Brito GA, et al. Caspase and bid involvement in Clostridium difficile toxin A-induced apoptosis and modulation of toxin A effects by glutamine and alanyl-glutamine in vivo and in vitro. Infect Immun. 2006;74(1):81–87. doi:10.1128/IAI.74.1.81-87.2006
   Web of Science ®Google Scholar
• Warren CA, Calabrese GM, Li Y, et al. Effects of adenosine A(2)A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice. BMC Infect Dis. 2012;12:13. doi:10.1186/1471-2334-12-13
   Web of Science ®Google Scholar
• Alonso CD, Mahoney MV. Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile. Infect Drug Resist. 2019;12:1–9. doi:10.2147/IDR.S159957
   Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305–317. doi:10.1056/NEJMoa1602615
   PubMed Web of Science ®Google Scholar
• Johnson S, Sambol S, Best E, et al. Efficacy of Bezlotoxumab in Patients Infected with Strains of Clostridium Difficile Associated with Poor Outcomes. IDWeek; 2016.
   Google Scholar
• Goldstein EJC, Citron DM, Gerding DN, et al. Bezlotoxumab for the prevention of recurrent Clostridioides difficile infection: 12-month observational data from the randomized phase III trial, MODIFY II. Clin Infect Dis. 2019. doi:10.1093/cid/ciz1151
   Web of Science ®Google Scholar
• Golan Y, Dupont HL, Aldomiro F, et al. Bezlotoxumab (BEZ) for prevention of Clostridium difficile infection (CDI) recurrence (rCDI): outcomes in patients with substantial renal impairment (SRI). Open Forum Infect Dis. 2017;4(Suppl 1):S387. doi:10.1093/ofid/ofx163.962
   Google Scholar
• Kelly CP, Wilcox M, Glerup H, et al. Characteristics and outcomes in patients with C. difficile infection (CDI) and inflammatory bowel disease: bezlotoxumab versus placebo. Gastroenterology. 2017;152(5):S340. doi:10.1016/S0016-5085(17)31400-2
   Web of Science ®Google Scholar
• Cornely OA, Mullane KM, Birch T, et al. Exploratory evaluation of bezlotoxumab on outcomes associated with Clostridioides difficile infection in MODIFY I/II participants with cancer. Open Forum Infect Dis. 2020;7(2):ofaa038. doi:10.1093/ofid/ofaa038
   Web of Science ®Google Scholar
• Critchley IA, Green LS, Young CL, et al. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother. 2009;63(5):954–963. doi:10.1093/jac/dkp041
   PubMed Web of Science ®Google Scholar
• Citron DM, Warren YA, Tyrrell KL, Merriam V, Goldstein EJ. Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrob Chemother. 2009;63(5):972–976. doi:10.1093/jac/dkp037
   PubMed Web of Science ®Google Scholar
• Ochsner UA, Bell SJ, O’Leary AL, et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother. 2009;63(5):964–971. doi:10.1093/jac/dkp042
   PubMed Web of Science ®Google Scholar
• Nayak SU, Griffiss JM, Blumer J, et al. Safety, tolerability, systemic exposure, and metabolism of CRS3123, a methionyl-tRNA synthetase inhibitor developed for treatment of Clostridium difficile, in a phase 1 study. Antimicrob Agents Chemother. 2017;61:8. doi:10.1128/AAC.02760-16
   Web of Science ®Google Scholar
• Lomeli BK, Galbraith H, Schettler J, et al. Multiple-ascending-dose phase 1 clinical study of the safety, tolerability, and pharmacokinetics of CRS3123, a narrow-spectrum agent with minimal disruption of normal gut microbiota. Antimicrob Agents Chemother. 2019;64:1. doi:10.1128/AAC.01395-19
   Web of Science ®Google Scholar
• Rashid MU, Dalhoff A, Backstrom T, et al. Ecological impact of MCB3837 on the normal human microbiota. Int J Antimicrob Agents. 2014;44(2):125–130. doi:10.1016/j.ijantimicag.2014.03.016
   PubMed Web of Science ®Google Scholar
• Deinove. Available from: http://www.deinove.com. Accessed June 1, 2020.
   Google Scholar
• Rashid MU, Dalhoff A, Weintraub A, Nord CE. In vitro activity of MCB3681 against Clostridium difficile strains. Anaerobe. 2014;28:216–219. doi:10.1016/j.anaerobe.2014.07.001
   PubMed Web of Science ®Google Scholar
• Freeman J, Pilling S, Vernon J, Wilcox MH. In vitro activities of MCB3681 and eight comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread. Antimicrob Agents Chemother. 2017;61:3. doi:10.1128/AAC.02077-16
   Web of Science ®Google Scholar
• Dalhoff A, Rashid MU, Kapsner T, Panagiotidis G, Weintraub A, Nord CE. Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle. Clin Microbiol Infect. 2015;21(8):767e761–764. doi:10.1016/j.cmi.2015.05.025
   Web of Science ®Google Scholar
• Mathur T, Barman TK, Kumar M, et al. In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018;62:4. doi:10.1128/AAC.02157-17
   Web of Science ®Google Scholar
• Kumar M, Mathur T, Joshi V, Upadhyay DJ, Inoue SI, Masuda N. Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota. Anaerobe. 2018;51:120–123. doi:10.1016/j.anaerobe.2018.04.017
   PubMed Web of Science ®Google Scholar
• Tyrrell KL, Citron DM, Merriam CV, Leoncio E, Goldstein EJC. In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria. Anaerobe. 2018;54:39–41. doi:10.1016/j.anaerobe.2018.04.010
   Web of Science ®Google Scholar
• Dennie J, Vandell AG, Inoue S, et al. A phase I, single-ascending-dose study in healthy subjects to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-2969b, a novel GyrB inhibitor. J Clin Pharmacol. 2018;58(12):1557–1565. doi:10.1002/jcph.1151
   Web of Science ®Google Scholar
• Vandell AG, Inoue S, Dennie J, et al. Phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DS-2969b, a novel GyrB inhibitor, in healthy subjects. Antimicrob Agents Chemother. 2018;62:5. doi:10.1128/AAC.02537-17
   Web of Science ®Google Scholar
• Daiichi-Sankyo. Available from: https://www.daiichisankyo.com/rd/pipeline/development_pipeline/. Accessed June 1, 2020.
   Google Scholar
• Leeds JA, Sachdeva M, Mullin S, Dzink-Fox J, Lamarche MJ. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother. 2012;56(8):4463–4465. doi:10.1128/AAC.06354-11
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2012;56(5):2493–2503. doi:10.1128/AAC.06305-11
   PubMed Web of Science ®Google Scholar
• Leeds JA. Antibacterials developed to target a single organism: mechanisms and frequencies of reduced susceptibility to the novel anti-Clostridium difficile compounds fidaxomicin and LFF571. Cold Spring Harb Perspect Med. 2016;6(2):a025445. doi:10.1101/cshperspect.a025445
   PubMed Web of Science ®Google Scholar
• Ting LS, Praestgaard J, Grunenberg N, Yang JC, Leeds JA, Pertel P. A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob Agents Chemother. 2012;56(11):5946–5951. doi:10.1128/AAC.00867-12
   PubMed Web of Science ®Google Scholar
• Bhansali SG, Mullane K, Ting LS, et al. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(3):1441–1445. doi:10.1128/AAC.04252-14
   PubMed Web of Science ®Google Scholar
• Mullane K, Lee C, Bressler A, et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(3):1435–1440. doi:10.1128/AAC.04251-14
   PubMed Web of Science ®Google Scholar
• Novartis. Available from: https://www.novartis.com/our-science/novartis-global-pipeline. Accessed June 1, 2020.
   Google Scholar
• Louie T, Morgan A, Larios O, Ravic M. Phase IIa Dose Escalation Treatment of Clostridioides Difficile-Associated Diarrhea with MGB-BP-3, a Novel First in Class DNA Minor Grove Binding Antibiotic. ECCMID; 2020.
   Google Scholar
• MGB biopharma. Available from: http://www.mgb-biopharma.com. Accessed June 1, 2020.
   Google Scholar
• Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J Antibiot (Tokyo). 1984;37(4):309–317. doi:10.7164/antibiotics.37.309
   PubMed Web of Science ®Google Scholar
• McCafferty DG, Cudic P, Frankel BA, Barkallah S, Kruger RG, Li W. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers. 2002;66(4):261–284. doi:10.1002/bip.10296
   PubMed Web of Science ®Google Scholar
• Boger DL. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev. 2001;21(5):356–381. doi:10.1002/med.1014
   PubMed Web of Science ®Google Scholar
• Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipeptide antibiotic. Ann Pharmacother. 2005;39(5):863–868. doi:10.1345/aph.1E397
   PubMed Web of Science ®Google Scholar
• Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother. 2003;51(Suppl 3):iii31–35. doi:10.1093/jac/dkg274
   PubMed Web of Science ®Google Scholar
• Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother. 2003;47(7):2334–2338. doi:10.1128/AAC.47.7.2334-2338.2003
   PubMed Web of Science ®Google Scholar
• Pelaez T, Alcala L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother. 2005;49(3):1157–1159. doi:10.1128/AAC.49.3.1157-1159.2005
   PubMed Web of Science ®Google Scholar
• Kraus CN, Lyerly MW, Carman RJ. Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model. Antimicrob Agents Chemother. 2015;59(5):2525–2530. doi:10.1128/AAC.04853-14
   PubMed Web of Science ®Google Scholar
• Pullman JPJ, Leach TS Ramoplanin versus vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study. 44th Intersci. Conf. Antimicrob. Agents Chemother; Washington, DC; 2004.
   Google Scholar
• Iscla I, Wray R, Blount P, et al. A new antibiotic with potent activity targets MscL. J Antibiot (Tokyo). 2015;68(7):453–462. doi:10.1038/ja.2015.4
   PubMed Web of Science ®Google Scholar
• Wolfe C, Pagano P, Pillar CM, Shinabarger DL, Boulos RA. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution. Diagn Microbiol Infect Dis. 2018;92(3):250–252. doi:10.1016/j.diagmicrobio.2018.06.002
   Web of Science ®Google Scholar
• Rao S, Prestidge CA, Miesel L, Sweeney D, Shinabarger DL, Boulos RA. Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis. J Antibiot (Tokyo). 2016;69(12):879–884. doi:10.1038/ja.2016.45
   PubMed Web of Science ®Google Scholar
• Wright L, Rao S, Thomas N, Boulos RA, Prestidge CA. Ramizol((R)) encapsulation into extended release PLGA micro- and nanoparticle systems for subcutaneous and intramuscular administration: in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2018;44(9):1451–1457. doi:10.1080/03639045.2018.1459676
   PubMed Web of Science ®Google Scholar
• Sibley K, Chen J, Koetzner L, et al. A 14-day repeat dose oral gavage range-finding study of a first-in-class CDI investigational antibiotic, in rats. Sci Rep. 2019;9(1):158. doi:10.1038/s41598-018-36690-9
   Web of Science ®Google Scholar
• Boulos & Cooper Pharmaceuticals. Available from: https://bouloscooper.com/research-and-development/antibiotic-drugs/. Accessed June 1, 2020.
   Google Scholar
• Kelly. Comparing the Effects of SMT19969, Vancomycin and Fidaxomicin on Sporulation of Several Clostridium Difficile Ribotypes. Copenhagen, Denmark: ECCMID; 2015.
   Google Scholar
• Basseres E, Endres BT, Khaleduzzaman M, et al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016;71(5):1245–1251. doi:10.1093/jac/dkv498
   PubMed Web of Science ®Google Scholar
• Corbett D, Wise A, Birchall S, et al. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother. 2015;70(6):1751–1756. doi:10.1093/jac/dkv006
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother. 2013;57(10):4872–4876. doi:10.1128/AAC.01136-13
   PubMed Web of Science ®Google Scholar
• Snydman DR, McDermott LA, Thorpe CM, et al. In Vitro Activity of Ridinilazole and Comparators Against Isolates of Clostridium Difficile Obtained from Stools of Patients as Part of US Surveillance in 2014. ASM Microbe; 2017.
   Google Scholar
• Snydman DR, McDermott LA, Thorpe CM, et al. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin. J Antimicrob Chemother. 2018;73(8):2078–2084. doi:10.1093/jac/dky135
   PubMed Web of Science ®Google Scholar
• Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH. SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother. 2015;70(1):182–189. doi:10.1093/jac/dku324
   PubMed Web of Science ®Google Scholar
• Vickers RJ, Tillotson GS, Nathan R, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017;17(7):735–744. doi:10.1016/S1473-3099(17)30235-9
   PubMed Web of Science ®Google Scholar
• Thorpe CM, Kane AV, Chang J, Tai A, Vickers RJ, Snydman DR. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin. PLoS One. 2018;13(8):e0199810. doi:10.1371/journal.pone.0199810
   PubMed Web of Science ®Google Scholar
• Theriot CM, Koenigsknecht MJ, Carlson PE, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114. doi:10.1038/ncomms4114
   PubMed Web of Science ®Google Scholar
• Qian X, Yanagi K, Kane AV, et al. Effect of Broad Vs. Narrow Spectrum Clostridioides Difficile Treatment on Human Stool Bile Acid Composition Over Time. IDWeek; 2019.
   Google Scholar
• Paul S, Vickers RJ, Garey KW, et al. Quality of Life Changes in Patients with Clostridium Difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared to Vancomycin (VAN). IDWeek; 2019.
   Google Scholar
• Guh AY, Mu Y, Winston LG, et al. Trends in U.S. Burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320–1330. doi:10.1056/NEJMoa1910215
   PubMed Web of Science ®Google Scholar
• Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008;359(18):1932–1940. doi:10.1056/NEJMra0707500
   PubMed Web of Science ®Google Scholar
• Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(Suppl 6):21–27. doi:10.1111/1469-0691.12046
   PubMed Web of Science ®Google Scholar
• Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281–289. doi:10.1016/S1473-3099(11)70374-7
   PubMed Web of Science ®Google Scholar
• Gerding DN, Cornely OA, Grill S, et al. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis. 2019;19(3):265–274. doi:10.1016/S1473-3099(18)30614-5
   PubMed Web of Science ®Google Scholar